1.
Extrapulmonary Tuberculosis by Nationality, the Netherlands, 1993–2001
2.
Percentage of patients with intermediate-thickness (1.2–3.5 mm) melanoma on trunk or limb in Southern Netherlands who underwent SLNB (Sentinel Lymph Node Biopsy).
3.
4.
5.
Survival of patients with intermediate-thickness (1.2–3.5 mm) melanoma on trunk or limb in Southern Netherlands diagnosed 2000–2016 followed up until Feb 2021 by SLNB (Sentinel Lym...
Characteristics of patients with intermediate thickness cutaneous melanoma (1.2–3.5 mm) on trunk or limb (n = 1989) diagnosed 2000–2016 in the Southern Netherlands.
Hazard Ratios (HR) of patients with intermediate-thickness (1.2–3.5 mm) melanoma diagnosed 2010–2016, followed-up until February 2021.
Studies on melanoma comparing outcome of SLNB and excision versus Obs (observation) after excision only.
A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands